Are NMDA receptor antagonists beneficial in the treatment of schizophrenia?

Journal of Psychiatric Research

Volumn 51, Issue 1, 2014, Pages 19-20

  Shim, Seong S ^a   Nadeem, Rashid ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Amantadine; Cognitive symptoms; Memantine; Meta analysis; NMDA receptor antagonists; Schizophrenia

Indexed keywords

AMANTADINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ADJUVANT THERAPY; CLINICAL OBSERVATION; COGNITION; COGNITIVE DEFECT; DATA MINING; DECISION MAKING; DOPAMINERGIC ACTIVITY; EXECUTIVE FUNCTION; FALSE POSITIVE RESULT; HUMAN; LETTER; MINI MENTAL STATE EXAMINATION; NEGATIVE SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA; SELECTION BIAS; TREATMENT OUTCOME; VELOCITY;

AMANTADINE; COGNITIVE SYMPTOMS; MEMANTINE; META-ANALYSIS; NMDA RECEPTOR ANTAGONISTS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84893935595     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.12.007     Document Type: Letter

References (20)

1. Cochrane review, Chapter 5, defining the review question and developing criteria for including studies.
2. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006, 26:365-384.
3. de Lucena D., Fernandes B.S., Berk M., Dodd S., Medeiros D.W., Pedrini M., et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry 2009, 70:1416-1423.
4. Flather M.D., Farkouh M.E., Pogue J.M., Yusuf S. Strengths and limitations of meta-analysis: larger studies may be more reliable. Control Clin Trials 1997, 18:568-579.
5. Harvey P.D. Cognitive impairment in schizophrenia: profile, course, and neurobiological determinants. Handb Clin Neurology 2012, 106:433-445.
6. Kishi T., Iwata N. NMDA receptor antagonists interventions in schizophrenia: meta-analysis of randomized, placebo-controlled trials. J Psychiatric Res 2013, 47:1143-1149.
7. Kuzuhara S. Drug-induced psychotic symptoms in Parkinson's disease. Problems, management and dilemma. J Neurol 2001, 248(Suppl. 3):28-31.
8. Lee J.G., Lee S.W., Lee B.J., Park S.W., Kim G.M., Kim Y.H. Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study. Psychiatry Investig 2012, 9:166-173.
9. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., Ioannidis J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Br Med J 2009, 339:b2700.
10. Lieberman J.A., Papadakis K., Csernansky J., Litman R., Volavka J., Jia X.D., et al. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacol 2009, 34:1322-1329.
11. Matsuda Y., Kishi T., Iwata N. Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia. J Psychiatric Res 2013, 47:2018-2020.
12. Moore D.J., Palmer B.W., Jeste D.V. Use of the mini-mental state exam in middle-aged and older outpatients with schizophrenia: cognitive impairment and its associations. Am J Geriatric Psychiatry 2004, 12:412-419.
13. Nakaya K., Nakagawasai O., Arai Y., Onogi H., Sato A., Miijima F., et al. Pharmacological characterizations of memantine-induced disruption of prepulse inhibition of the acoustic startle response in mice: involvement of dopamine D2 and 5-HT2A receptors. Behav Brain Res 2011, 218:165-173.
14. Rezaei F., Mohammad-Karimi M., Seddighi S., Modabbernia A., Ashrafi M., Salehi B., et al. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2013, 33:336-342.
15. Ridha B.H., Josephs K.A., Rossor M.N. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 2005, 65:481-482.
16. Riedel G., Platt B., Micheau J. Glutamate receptor function in learning and memory. Behav Brain Res 2003, 140:1-47.
17. Silver H., Goodman C., Isakov V., Knoll G., Modai I. A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients. Int Clin Psychopharmacol 2005, 20:319-326.
18. Toide K. Effects of amantadine on dopaminergic neurons in discrete regions of the rat brain. Pharmacol Res 1990, 7:670-672.
19. Tsai G.E., Lin P. Strategies to enhance N-methyl-daspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharmacol Des 2010, 16:522-537.
20. Walker E., Hernandez A.V., Kattan M.W. Meta-analysis: Its strengths and limitations. Clevel Clin J Med 2008, 75:431-439.